CLBS - Cend Roche team up for trial of CEND-1/Tecentriq in pancreatic cancer

• Cend Therapeutics is collaborating with Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) to evaluate CEND-1 in combination with Roche's Tecentriq (atezolizumab), and standard-of-care chemotherapy, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
• Under the agreement, the Swiss pharma giant will be responsible for operational management of the trial while both companies will share equally in the costs of the CEND-1 treatment arms in the study, said Caladrius Biosciences ( NASDAQ: CLBS ) — which is merging with Cend.
• The trial will be conducted as part of Roche's Morpheus Platform, which is a collection of phase 1b/2 trials in multiple cancer indications.
• The phase 1b/2 study will be conducted at sites in the U.S., Germany, Spain and South Korea.

For further details see: